Monthly Archives: March 2017

//March

Consensus meeting supports plans to launch EDOR®

The Emotra clinical multicentre study, EUDOR-A, which was started during the spring of 2014, has been finalized. The study clearly demonstrates a lower number of suicides in comparison with previous studies, particularly and statistically significantly in the hyporeactive group. During the meeting between participants in the study in Rome the last two days, 29th to [...]

By | March 31st, 2017|INVESTERARE|Comments Off on Consensus meeting supports plans to launch EDOR®

European Commission Horizon 2020 – application rejected

The European Commission, EC, has rejected Emotra’s application, submitted in January 2017, for approximately 3 MEUR, intended for three purposes: First of all to finance EUDOR-Y, a clinical multi-centre study on young people, secondly to develop EDOR® Interconnect, and thirdly to further develop our hardware and software solutions. Similar to last time, the application cleared [...]

By | March 13th, 2017|INVESTERARE|Comments Off on European Commission Horizon 2020 – application rejected